BioSpace News Archive

Sorrento Therapeutics, Inc. (NASDAQ: SRNE, “Sorrento”) today announced that Dr. Henry Ji, Chairman and CEO of Sorrento and Executive Chairman of Scilex Holding Company (“Scilex”), will participate in the B. Riley Virtual Neuro & Opthalmology Healthcare Conference at 10:00AM ET on April 27, 2022.

AffyImmune Therapeutics, Inc. announced today the addition of Sonal Gupta , MD, PhD to its senior leadership team as Senior Vice President and Head of Clinical Development.

Beaconcure has announced that this May, it will present at two major international conferences - PHUSE US Connect 2022 (May 1-4 in Atlanta, Georgia) and PharmaSUG 2022 (May 22-25 in Austin, Texas).

Sentynl Therapeutics, Inc. (Sentynl), a U.S.-based biopharmaceutical company focused on bringing innovative therapies to patients living with rare diseases, owned by Zydus Lifesciences Ltd. (formerly known as Cadila Healthcare Ltd.), today announced the continued availability of NULIBRY (fosdenopterin) for Injection and the launch of Sentynl Cares.

Evofem Biosciences, Inc., (Nasdaq: EVFM) will hold a webcast and conference call to discuss financial results and business highlights for the first quarter ended March 31, 2022.

Orca Bio, a clinical-stage biotechnology company developing purified, high-precision cell therapies for the treatment of cancer, genetic blood disorders and autoimmune diseases, today announced that positive new data were presented at the 2022 Transplantation & Cellular Therapy ASTCT and CIBMTR Tandem Meetings in Salt Lake City, Utah.

Cyteir Therapeutics, Inc., a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer, announced that Adam Veness, Esq. has joined Cyteir as General Counsel.

Mawi DNA Technologies, a biotechnology company focusing on the development of innovative technologies for biosampling, announces that Prime Discoveries has successfully developed CovidDetect™, a rapid isothermal amplification diagnostic assay for detecting SARS-CoV-2.

ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, announced today that the first participants have been enrolled in a study that is part of an 800-site master protocol trial for non-small cell lung cancer (NSCLC).

GlycoMimetics, Inc., announces that it will host a conference call and webcast to report first quarter financial results on Thursday, April 28, 2022, at 8:30 a.m. ET.